Table 8 Dosimetric comparison of organs at risk (OARs) for the 3 treatment plans

V₃₅

34.7 [23.9–66.1]

13.0 [7.0–29.3]*

10.6 [3.5–17.1]*

0.002

V₂₅

50.3 [41.2–74.3]

30.0 [18.5–53.0]^&

30.4 [10.8–37.4]*

0.020

V₁₅

64.9 [51.2–81.0]

68.0 [52.0–73.2]

57.1 [33.8–80.6]

0.796

Peritoneum dose (%)

V_50.4

35.8 [18.0–50.0]

3.6 [1.0–5.0]*

2.7 [0.5–5.2]*

0.001

V₄₀

51.7 [28.0–73.0]

12.0 [7.0–21.0]*

*

0.002

V₃₀

58.7 [35.2–79.7]

27.0 [20.0–37.0]*

23.6 [17.5–34.6]*

0.013

V₂₅

66.7 [32.5–83.0]

45.0 [33.7–52.0]

36.6 [30.4–45.5]

0.147

Rectum dose (%)

V_50.4

24.4 [15.6,–52.6]

2.2 [0.0–13.4]*

5.3 [0.3–7.4]*

0.003

V₄₀

97.5 [94.2–100.0]

37.0 [26.0–68.4]*

34.1 [26.2–40.6]*

< 0.001

V₃₀

97.5 [96.3–100.0]

86.5 [69.3–90.0]

56.4 [49.3–66.0]*^§

< 0.001

Bladder dose (%)

V_50.4

40.7 [31.2–46.7]

2.0 [1.0–14.0]*

5.7 [0.7–13.3]*

0.001

V₄₀

100.0 [99.8–100.0]

28.0 [23.3–34.1]*

28.6 [21.3–46.1]*

< 0.001

V₃₀

100.0 [100.0–100.0]

59.5 [52.0–71.0]*

50.5 [43.2–73.6]*

< 0.001

Bone marrow dose (%)

V₅₀

27.8 [24.1–29.2]

4.0 [2.7–5.0]*

5.5 [3.0–8.1]*

< 0.001

V₄₀

44.0 [39.7–45.5]

16.0 [13.0–17.0]*

19.6 [16.9–23.0]*

< 0.001

V₃₀

58.9 [54.8–62.9]

37.0 [34.2–38.5]*

39.2 [38.0–45.8]*

< 0.001

V₂₀

88.8 [81.5–91.3]

70.0 [63.0–75.4]*

70.4 [67.1–73.3]*

0.002

V₁₀

91.9 [84.4–95.6]

89.8 [87.0–94.0]

90.2 [87.1–92.7]

0.936